Eli Lil­ly un­veils piv­otal da­ta from the star of its Der­mi­ra buy­out. But can it ri­val Dupix­ent in atopic der­mati­tis?

It’s been just over a year and a half since Eli Lil­ly shelled out $1.1 bil­lion for Der­mi­ra and its old Roche castoff le­brik­izum­ab for atopic der­mati­tis. Now the phar­ma says it has the Phase III re­sults it was look­ing for — but are they good enough to ri­val Re­gen­eron and Sanofi’s block­buster Dupix­ent?

Ac­cord­ing to topline re­sults, the IL-13 in­hibitor helped more than half of adults and ado­les­cents in two tri­als achieve at least 75% clear­ance of their eczema (mea­sured by the Eczema Area and Sever­i­ty In­dex). The stud­ies met the pri­ma­ry and key sec­ondary end­points at Week 16, Eli Lil­ly said on Mon­day, in­clud­ing skin clear­ance and itch im­prove­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER